Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin

Cancer Treatment–Related Cardiotoxicity: Current State of Knowledge and Future Research Priorities

(2014) Nonniekaye Shelburne et al.   JNCI-Journal of the National Cancer Institute

Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways

(2014) Karina Huynh et al.   PHARMACOLOGY & THERAPEUTICS

Emerging Paradigms in Cardiomyopathies Associated With Cancer Therapies

(2013) Bonnie Ky et al.   CIRCULATION RESEARCH

Cardiotoxicity Debated for Anthracyclines and Trastuzumab in Breast Cancer

(2013) Vicki Brower   JNCI-Journal of the National Cancer Institute

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Left Ventricular Longitudinal Strain with Anthracycline Chemotherapy in Adolescents Precede Subsequent Decreased Left Ventricular Ejection Fraction

(2012) Joseph T. Poterucha et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Cardiac-Specific Over-Expression of Epidermal Growth Factor Receptor 2 (ErbB2) Induces Pro-Survival Pathways and Hypertrophic Cardiomyopathy in Mice

(2012) Polina Sysa-Shah et al.   PLoS One

Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients

(2011) S Romano et al.   BRITISH JOURNAL OF CANCER

Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis

(2011) Ornella Garrone et al.   Cardiovascular Toxicology

Cardiovascular Disease

(2011) Ming Hui Chen et al.   CIRCULATION RESEARCH

Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy

(2011) P. W. Stoodley et al.   European Journal of Echocardiography

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

(2011) Barry H. Trachtenberg et al.   PEDIATRIC CARDIOLOGY

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

(2010) S. Verma et al.   ANNALS OF ONCOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

(2009) P. J. Barrett-Lee et al.   ANNALS OF ONCOLOGY

Doxorubicin Cardiomyopathy

(2009) Kanu Chatterjee et al.   CARDIOLOGY

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide

(2009) Mauro Feola et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cardiovascular Complications of Cancer Therapy

(2009) Edward T.H. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients

(2008) Marianne Ryberg et al.   JNCI-Journal of the National Cancer Institute

Monitoring of Anthracycline-Induced Cardiotoxicity

(2007) Abigail Jannazzo et al.   ANNALS OF PHARMACOTHERAPY